Please provide your email address to receive an email when new articles are posted on . The FDA approved a third-generation PCSK9 inhibitor to reduce cholesterol in certain high-risk patients. The ...
In patients with advanced epithelial ovarian cancer, first-line maintenance therapy with PARP inhibitors was associated with a progression-free survival benefit compared with standard chemotherapy ...
Enlicitide, an oral PCSK9 inhibitor, reduced LDL-C by nearly 60% in adults with or at risk for ASCVD. The medication offers a daily oral alternative to injectable PCSK9 inhibitors, potentially ...
Novelwise Pharmaceutical is a biopharmaceutical company dedicated to the discovery and development of a series of histone deacetylase (HDAC) inhibitor programs for oncology and other diseases with ...
BeOne Medicines and AbbVie’s Pharmacyclics have decided to voluntarily dismiss the patent lawsuit the Big Pharma firm brought against its competitor over their BTK inhibitors. The patent covers a ...
The cancer drugs called PARP inhibitors have a puzzling reputation: even though they are treatment mainstays for multiple forms of cancer, they can damage cancer-killing T cells and disrupt the ...
When canagliflozin (Invokana) was approved in 2013, the SGLT2 inhibitor was touted as a first in a new medication class that was, at the time, the only oral, once-daily medication to reduce blood ...
Phase 2 study of letrozole, abemaciclib, and metformin in estrogen receptor (ER)–positive recurrent endometrial cancer (EC). This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...
SHANGHAI--(BUSINESS WIRE)--#D3Bio--D3 Bio, a clinical-stage biotechnology company pioneering precision oncology therapies, today announced the simultaneous publication of landmark clinical data on its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback